Cellulitis Completed Phase 3 Trials for Dalbavancin (DB06219)

Also known as: Cellulitis, unspecified

IndicationStatusPhase
DBCOND0014773 (Cellulitis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02127970Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsTreatment
NCT01339091Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsTreatment
NCT01431339Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsTreatment